期刊文献+

盐酸哌罗匹隆治疗首发精神分裂症阴性症状与认知功能临床对照 被引量:7

Hydrochloric acid piperazine treatment starting the negative symptoms of schizophrenia and cognitive function in controlled clinical
原文传递
导出
摘要 目的:比较盐酸哌罗匹隆与舒比利治疗首发精神分裂症的临床疗效和安全性。方法:将68例首发精神分裂症患者随机分成治疗组与对照组,各34例。治疗组予盐酸哌罗匹隆治疗,对照组予舒比利治疗,两组治疗均8周。采用阳性与阴性症状量表(PANSS)评定疗效,采用数字划销测验(NCT)评定认知功能,以不良反应量表(TESS)及相关辅助检查评价安全性。结果:治疗组与对照组显效率分别为70.6%,76.5;PANSS阴性症状评分,两组在治疗第4周末开始与治疗前评分差异有统计学意义(P<0.05);NCT测评,治疗第8周末,治疗组与对照组在净分和失误率上比较,差异均具有统计学意义(P<0.01),两组在净分和失误率上分别与治疗前比较,两组净分均较治疗前显著提高,失误率均显著下降,差异均具有统计学意义(P<0.01或P<0.05);治疗组不良反应少。结论:盐酸哌罗匹隆治疗首发精神分裂症阴性症状疗效与舒比利相当,认知功能改善明显,不良反应少,耐受性好。 Objective: Compared with Hydrochloric acid piperazine and sulpiride treatment starting schizophrenia clinical efficacy and safety. Methods : 68 cases of first episode schizophrenia patients were randomly divided into treatment group and control group, all 34 cases. Treatment group to the piperazine, control group to the sulpiride, treatment in both groups 8 weeks. With the Positive and negative syndrome scale (PANSS) to evaluate the efficacy, the use of the number cancellation test (NCT) to assess cognitive function, Treatment Emergent Symptom Scale (TESS)and secondary inspection to evaluation security. Results: Treatment group and control group significant efficiency was respectively 70. 6%, 76. 5% ;PANSS negative symptom score, the two groups in treatment 4 weeks before treatment, differences in scores was statistically significant (P 〈0. 05) ;NCT evaluation, and treatment of the 8th week, the treatment and control groups in the net points and error rate, the differences were statistically significant (P 〈 0. 01 ), the two groups on the net points and error rate respectively, compared with before treatment, two group net points than before treatment was significantly im- proved, a significant reduction in error rate, the differences were statistically significant (P 〈 0. 01 or P 〈 0. 05) ; treatment group less adverse reactions. Conclusion: Hydrochloric acid piperazine treatment of the negative symptoms of first episode schizophrenia efficacy and sulpiride, cognitive function improved significantly fewer adverse reactions, and well tolerated.
出处 《中国药物滥用防治杂志》 CAS 2013年第2期89-92,共4页 Chinese Journal of Drug Abuse Prevention and Treatment
关键词 盐酸哌罗匹隆 舒比利 首发精神分裂症 阴性症状 认知功能 Hydrochloric Acid Piperazine Sulpiride Episode Schizophrenia Negative Symptoms Cognitive Function
  • 相关文献

参考文献7

二级参考文献68

  • 1房茂胜,李乐华,翟金国,叶萌.新型抗精神病药:哌罗匹隆[J].中国新药与临床杂志,2006,25(7):548-551. 被引量:32
  • 2SmallJG CaseyD ArvanitisLA etal 赵靖平 朱荣华译.喹硫平-一种新的非典型抗精神病药[J].国外医学:精神病学分册,2000,27:36-39.
  • 3TAKAHASHI Y, KUSUMI I, ISHIKANE T, et al. In vivo occupation of dopamine DI ,D2 and serotonin 2A receptors by novel antipsychotic drug, SM-9018 and its metabolite, in rat brain[J].Neural Transm, 1998,105(2-3) : 181-191.
  • 4OHNO Y. Pharmacological characteristics of perospirone hydrochloride, a novel antipsychotic agent[J]. Nippon Yakurigaku Zasshi ,2000,116(4) :225-231.
  • 5SHIWA T,AMANO T, MATSUBAYASHI H, et al. Perospirone,a novel antipsychotic agent, hyperpolarizes rat dorsal raphe neurons via 5-HTIA receptor[J]. Pharmacol Sci ,2003,93 ( 1 ) : 114-117.
  • 6IWAKAWA M, TERAO T,SOYA A, et al. A novel antipsychotic, perospirone, has antiserotonergic and antidopaminergie effects in human brain: findings from neuroendocrine challenge tests[J].Psychopharmacology, 2004,176 (3 -4 ) : 407-411.
  • 7KAZUTOYO I, SHIN I, AKINORI U, et al. Phase I study of perospirone HCL (SM-9018)[J]. Clinical Report,1997,31 (6):188.
  • 8YASUI-FURUKORI N, FURUKORI H, NAKAGAMI T, et al.Steady-state pharmacokinetics of a new antipsychotic agent perospirnoe and its active metabolite, and its relationship with prolactin response[J]. Ther Drug Monit, 2004,26(4):361-365.
  • 9KITAMURA A, MIZUNO Y, NATSUI K, et al. Characterization of human cytochrome P450 enzymes involved in the in vitro metabolism of perospirone[J]. Biopharm Drug Dispos, 2005,26 (2) :59-65.
  • 10SHIMAKURA J, TANI N, MIZUNO Y, et al. In vitro drug-drug interactions with perospirone and concomitantly administered drugs in human liver microsomes[J]. Eur J Drug Metab Pharmacokinet ,2003,28( 1 ) :67-72.

共引文献72

同被引文献72

  • 1黄晓东.哌罗匹隆治疗首发女性精神分裂症40例探讨[J].求医问药(下半月),2013(2):718-719. 被引量:4
  • 2涂继莹,左笑丛,李焕德.非典型抗精神病药——哌罗匹隆[J].中国临床药理学杂志,2007,23(2):157-160. 被引量:25
  • 3中华医学会精神科分会.中国精神障碍分类与诊断标准:CCMD-3[M].3版.济南:山东科学技术出版社,2001:87-89.
  • 4Stip E.Cognition,schizophrenia and the effect of antipsychotics[J].Encephale,2006,32(3):341.
  • 5Lindenmayer JP,Harvey PD,Khan A,et al.Schizophrenia:measurements of psychopathology psychiatry[J].Psychiatr Clin North Am,2007,30(3):339.
  • 6Maat A,Fett AK,Derks E,et al.Social cognition and quality of life in schizophrenia[J].Schizophr Res,2012,137(1/2/3):212.
  • 7Sidlova M,Prasko J,Jelenova D,et al.The quality of life of patients suffering from schizophrenia:comparison with healthy controls[J].Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub,2011,155(2):173.
  • 8Kucharska-Pietura K,Mortimer A,Tylec A,et al.Social cognition and visual perception in schizophrenia inpatients treated with first-and second-generation antipsychotic drugs[J].Clin Schizophr Relat Psychoses,2012,6(1):14.
  • 9Green MF,Nuechtedein KH,Gold JM,et al.Approaching a consensus cognitive battery for clinical trials in schizophrenia:the NIMH-MATRICS conference to select cognitive domains and criteria[J].Biol Psychiatry,2004,56(5):301.
  • 10Figueira ML,Brissos S.Measuring psychosocial outcomes in schizophrenia patients[J].Curr Opin Psychiatry,2011,24(2):91.

引证文献7

二级引证文献36

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部